TI
CPRX

Trexquant Investment’s Catalyst Pharmaceutical CPRX Stock Holding History

Trexquant Investment’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.53M Sell
223,252
-25,842
-10% -$616K 0.04% 605
2025
Q4 		$5.81M Buy
249,094
+124,762
+100% +$2.78M 0.05% 523
2025
Q3 		$2.45M Buy
124,332
+82,011
+194% +$1.69M 0.03% 831
2025
Q2 		$918K Sell
42,321
-179,499
-81% -$4.24M 0.01% 1129
2025
Q1 		$5.38M Buy
221,820
+15,331
+7% +$345K 0.06% 474
2024
Q4 		$4.31M Sell
206,489
-89,171
-30% -$1.92M 0.05% 576
2024
Q3 		$5.88M Buy
295,660
+174,931
+145% +$3.24M 0.07% 412
2024
Q2 		$1.87M Buy
120,729
+41,979
+53% +$654K 0.03% 783
2024
Q1 		$1.26M Buy
+78,750
New +$1.19M 0.03% 834
2023
Q1 		– Sell
-147,657
Closed -$2.75M – 1483
2022
Q4 		$2.75M Sell
147,657
-70,049
-32% -$1.08M 0.08% 322
2022
Q3 		$2.79M Buy
217,706
+130,755
+150% +$1.55M 0.1% 259
2022
Q2 		$610K Buy
86,951
+14,094
+19% +$103K 0.03% 714
2022
Q1 		$604K Buy
72,857
+20,888
+40% +$148K 0.03% 679
2021
Q4 		$352K Buy
+51,969
New +$342K 0.02% 834

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Trexquant Investment's CPRX Position: Q1 2026 in Review

Trexquant Investment reduced its Catalyst Pharmaceutical (CPRX) stake by 10% in Q1 2026, selling an estimated $616K and leaving 223,252 shares worth $5.53M. The position accounts for 0.04% of the portfolio, ranked #605.

Trexquant Investment first reported a position in CPRX in Q4 2021 and has held it in 14 quarters since. The position peaked at $5.88M in Q3 2024. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Trexquant Investment held 223,252 shares of Catalyst Pharmaceutical worth $5.53M as of Q1 2026.
  • Trexquant Investment sold 25,842 Catalyst Pharmaceutical shares in Q1 2026, an estimated $616K.
  • Catalyst Pharmaceutical made up 0.04% of Trexquant Investment's portfolio in Q1 2026, its #605 holding.
  • Trexquant Investment first reported a position in Catalyst Pharmaceutical in Q4 2021 and has held it in 14 quarters since.
  • Trexquant Investment's Catalyst Pharmaceutical position peaked at $5.88M in Q3 2024.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Trexquant Investment's 13F filing for Q1 2026, filed 15 May 2026.